Table 2 Percentage of survived HCC cells treated with Gefitinib (IC50) in the presence of ECM proteins
From: Laminin-5 offsets the efficacy of gefitinib (‘Iressa’) in hepatocellular carcinoma cells
Sk-Hep1 | Alexander | HLF | HepG2 | |
|---|---|---|---|---|
Gefitinib | 50±3.7 | 50±1.3 | 50±8.4 | 50±10 |
Gefitinib+LN-5 | 78±6.9 | 84±11.0 | 81±5.8 | 81±09 |
Gefitinib+Coll I | 62±6.9 | 55±7.9 | 56±9.5 | 58±6.8 |
Gefitinib+Coll IV | 63±7.0 | 57±2.3 | 58±9.2 | 61±5.9 |
Gefitinib+Fib | 61±6.6 | 55±4.8 | 57±6.2 | 59±7.9 |
Gefitinib+FN | 62±5.4 | 57±1.8 | 55±8.3 | 59±6.9 |
Gefitinib+LN-1 | 57±9.7 | 54±2.7 | 59±5.0 | 55±4.7 |
Gefitinib+VN | 59±7.5 | 58±1.0 | 56±5.6 | 57±6.8 |
